Publikationsdatenbank

Holistic analysis of gene expression (NGS, proteomics) and functions in animal diseases:
canine cancer and Varroa treatment in honeybees as examples (2023)

Art

Vortrag

Autoren

Einspanier, Ralf (WE 3)

Gutierrez-Riquelme, Tania (WE 3)

Genath, Antonia (WE 3)

Mating, Moritz (WE 3)

Stein, Torsten (WE 3)

Kongress

XXVIIth Biochemistry Congress

High Tatras, Slovakia, 13.09.2023

Quelle

XXVIIth biochemistry congress of Slovak and Czech societies for biochemistry and molecular biology with cooperation of Hungarian and Ukrainian biochemical societies : FEBS3+ meeting : programme & abstract book

— S. 48

Verweise

URL (Volltext): https://ssbmb2023.sk/img/cms/library/FEBS-WEBNEW_final_programme_abstract_book.pdf

Kontakt

Institut für Veterinär-Biochemie

Oertzenweg 19 b
14163 Berlin
+49 30 838 62225
biochemie@vetmed.fu-berlin.de

Abstract / Zusammenfassung

Specific molecular analysis of serious diseases in veterinary medicine is particularly ambitious because there are many different animal species, most of which have different metabolic pathways and whose genome or proteome is rarely fully available. In order to diagnose and subsequently treat important diseases in the diverse species (most interesting are livestock and companion animals), appropriate samples paired with modern molecular biological analysis techniques should be necessary. Here, two animal systems will be introduced as examples for elucidating first molecular basis for dysregulated cellular signaling cascades: First, (I) selected canine cancer cell lines secreting extracellular vesicles (EV) are monitored for specifically regulated protein abundance compared to controls. Dysregulated candidate genes found in EVs may possess the potential as further diagnostic tools. Second, (II) a project is presented deciphering the molecular mode of action of formic acid (FA), a common treatment against the honeybee parasite, Varroa destructor. The identification of potentially involved insect enzyme systems may thus contribute to a better understanding of the mode of action as well as to a more optimized FA-treatment in the future. The aims of these two case studies were to detect new target molecules (biomarker), by (I) searching for EV-based peripheral target molecules to diagnose dog cancer in early stages, and (II) to clarify the mode of action of the frequently used varroazide formic acid (FA). These findings should improve the intended cellular effects and the development of more specific therapies in both species. By use of biochemical (cell culture, EV isolation and characterization, 2D electrophorese and/or mass spectroscopy, enzyme activity measurement, computational protein modelling) as well as molecular genetic methods (RT-qPCR, RNAseq, miRNA, RNAi, recombinant protein expression) first insights in differently regulated disease-/pathogen-related genes and proteins were enabled. Based on modern molecular methods combined with computational pathways analysis, we were able to select significantly regulated transcripts and proteins in both animal systems. Significantly regulated candidate gene products were identified and verified for the first time in dogs and honeybees. In conclusion, our research will (I) provide novel EV-based molecular biomarkers for selected cancer cells in dogs that may be useful for cancer diagnosis and therapy. Further basic results should (II) allow us to better understand the molecular mechanisms of FA treatment against Varroa in honeybees enabling more efficient treatment strategies less harmful to honeybees. This knowledge of new effector molecules will be of great benefit for both diagnostics and therapy in canine cancers or threats to honeybee health.